Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease

被引:70
作者
Nseir, W. [2 ,4 ]
Shalata, A. [1 ]
Marmor, A. [3 ]
Assy, N. [1 ,4 ]
机构
[1] Ziv Med Ctr, Liver Unit, IL-13100 Safed, Upper Galilee, Israel
[2] Holy Family Hosp, Dept Internal Med, Nazareth, Israel
[3] Ziv Med Ctr, Dept Cardiol, IL-13100 Safed, Upper Galilee, Israel
[4] Technion Israel Inst Technol, Fac Med, Haifa, Israel
关键词
Fatty liver; Cardiovascular disease; Coronary artery diseases; Mechanism; NAFLD; Steatohepatitis; C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; HEPATIC STEATOSIS; PHYSICAL-ACTIVITY; RISK-FACTORS; INDEPENDENT PREDICTOR; POSTPRANDIAL LIPEMIA; INCREASED PREVALENCE; LIPID-PEROXIDATION;
D O I
10.1007/s10620-011-1767-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The most common cause of death in patients with nonalcoholic fatty liver disease (NAFLD) is coronary artery disease (CAD), not chronic liver disease. Fatty liver increases cardiovascular risk by classical (dyslipidemia, hypertension, diabetes) and by less conventional mechanisms. Common pathways involved in the pathogenesis of fatty liver and CAD includes hepatic insulin resistance and sub clinical inflammation. The hepatic insulin resistance state of fatty liver infiltration is characterized by increased FFA, which causes lipotoxicity and impairs endothelium-dependent vasodilatation, increases oxidative stress, and has a cardio toxic effect. Additional metabolic risk factors include leptin, adiponectin, pro inflammatory cytokines [such as IL-6, C-reactive protein and plasminogen activator inhibitor-1 (PAI-1)], which together lead to increased oxidative stress and endothelial dysfunction, finally promoting coronary artery disease (CAD). When classical risk factors are superimposed on fatty liver accumulation, they may further increase the new metabolic risk factors, exacerbating CAD. The clinical implication is that patients with NAFLD are at higher risk (steatohepatitis, diabetes, obesity, atherogenic dyslipidemia) and should undergo periodic cardiovascular risk assessment including the Framingham score, cardiac effort test, and measurement of intimae-media thickening of the carotids arteries. This may improve risk stratification for CAD.
引用
收藏
页码:3439 / 3449
页数:11
相关论文
共 142 条
[1]   Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome [J].
Abid, Ali ;
Taha, Ola ;
Nseir, William ;
Farah, Raymond ;
Grosovski, Maria ;
Assy, Nimer .
JOURNAL OF HEPATOLOGY, 2009, 51 (05) :918-924
[2]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[3]   Overproduction of large VLDL particles is driven by increased liver fat content in man [J].
Adiels, M ;
Taskinen, MR ;
Packard, C ;
Caslake, MJ ;
Soro-Paavonen, A ;
Westerbacka, J ;
Vehkavaara, S ;
Hakkinen, A ;
Olofsson, SO ;
Yki-Jarvinen, H ;
Borén, J .
DIABETOLOGIA, 2006, 49 (04) :755-765
[4]   Diabetic dyslipidaemia [J].
Adiels, Martin ;
Olofsson, Sven-Olof ;
Taskinen, Marja-Riitta ;
Boren, Jan .
CURRENT OPINION IN LIPIDOLOGY, 2006, 17 (03) :238-246
[5]   Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men - A general population study [J].
Adlerberth, AM ;
Rosengren, A ;
Wilhelmsen, L .
DIABETES CARE, 1998, 21 (04) :539-545
[6]   Obstructive sleep apnea syndrome and fatty liver: Association or causal link? [J].
Ahmed, Mohamed H. ;
Byrne, Christopher D. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (34) :4243-4252
[7]  
Akabame S, 2008, CIRC J, V72, P618
[8]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[9]   The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].
Angulo, Paul ;
Hui, Jason M. ;
Marchesini, Giulio ;
Bugianesi, Ellisabetta ;
George, Jacob ;
Farrell, Geoffrey C. ;
Enders, Felicity ;
Saksena, Sushma ;
Burt, Alastair D. ;
Bida, John P. ;
Lindor, Keith ;
Sanderson, Schuyler O. ;
Lenzi, Marco ;
Adams, Leon A. ;
Kench, James ;
Therneau, Terry M. ;
Day, Christopher P. .
HEPATOLOGY, 2007, 45 (04) :846-854
[10]   Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients [J].
Antonopoulos, S ;
Mikros, S ;
Mylonopoulou, M ;
Kokkoris, S ;
Giannoulis, G .
ATHEROSCLEROSIS, 2006, 184 (01) :233-234